HOOKIPA Pharma Inc (HOOK)

[Just-Keep-Trying]

HOOK: Good summary of what is transpiring behind HOOK here on the "PULSE 2.0" website:
https://pulse2.com/hookipa-pharma-nasdaq-hook-stock-why-the-price-surged-today/

[TimeFades]

Yep looks like multi day runner

[Just-Keep-Trying]

HOOK: 56% UP this day, & climbing. (You might take a look.)

[Just-Keep-Trying]

HOOK should at least Close today up circa 92%; it's a very REASONABLY-priced NASDAQ stock. And, of course, its GILEAD partner ain't no small-potatoes Big Pharma company!

[TimeFades]

Nice churn let’s see . Not much else going on in the mkt today let’s pump this thing

[Just-Keep-Trying]

HOOK=$$$$: If this kind of news doesn't send a (low-priced) NASDAQ stock flying, well, then WHAT the frick can????
https://eresearch.fidelity.com/eresearch/evaluate/news/basicNewsStory.jhtml?symbols=HOOK&storyid=202202151722MIDNIGHTUSEQUITY_A2599751&provider=MIDNIGHT&product=USEQUITY&sb=1

[alchemytrader]

somebody knows something...

[MADDSTACKER]

Let’s f goooo

[trendzone]

Shorts caught on the hook, and getting squeezed on big news.

[MADDSTACKER]

Grabbed 1k here figured why not

[stockguard]

HOOK- Fascinating SEC filing yesterday. Management is waiving a portion of their salary for six months (to conserve cash?) and instead accepting restricted stock.
Effective February 1, 2022, the Chief Executive Officer, Chief Financial Officer and Chief Medical Officer of HOOKIPA Pharma Inc. (the “Company”), along with other members of the Company’s executive team (the “Executive Team”), waived a portion of their base salaries, for the six months ending June 30, 2022. In exchange for such waiver of salary, each such officer received that number of shares of the Company’s fully vested common stock having a value equal to their foregone salary (determined based on a fixed price of $3.00 per share), resulting in the issuance of an aggregate of 112,549 shares of common stock. Pursuant to such waiver, the Company’s Chief Executive Officer, Joern Aldag, waived 50 percent of his base salary for the six months ending June 30, 2022 in exchange for a commensurate stock grant of 47,824 fully vested shares of common stock. The Company’s Chief Financial Officer, Reinhard Kandera, and Chief Medical Officer, Igor Matushansky, each waived 20 percent of their base salaries for the six months ending June 30, 2022 in exchange for a commensurate stock grant of 14,056 and 14,933 fully vested shares of common stock, respectively. All of the officers noted above, along with other members of the Executive Team, also received 50 percent of their 2021 annual bonus in the form of a stock option grant, determined based on a value of $3.00 per share, resulting in the issuance of a total number of 145,071 options. Messrs. Aldag and Kandera and Dr. Matushansky each received 39,853, 23,427 and 24,888 options, respectively. The granted options have an exercise price of $1.50 per share, the closing price of the Company’s common stock on January 31, 2022. https://seekingalpha.com/filing/6173820

[KeepOn]

Garnering much interest, now.

[stockguard]

Date of Earliest Transaction (Month/Day/Year)
12/21/2021 just reported:

SEC Form 4: Matushansky Igor exercised 22,853 shares at a strike of $0.10 and sold $37,223 worth of shares (14,949 units at $2.49), increasing direct ownership by 10% to 85,307 units to satisfy withholding tax
https://quantisnow.com/insight/2246285?s=s

[stockguard]

At 52 week low this is very oversold for what the company has in trials.
Added 10,000 shares for this years comeback on trial update's. The below are must listen to get a true perspective.

Past Events
H.C. Wainwright BioConnect Conference
Jan 10 from 7:00 AM EST to Jan 13, 2022
Webcast
JMP Securities Hematology and Oncology Summit
Dec 7, 2021 at 1:20 PM EST
Webcast

https://ir.hookipapharma.com/events

[stockguard]

JMP Securities Hematology and Oncology Summit
December 7, 2021 1:20 p.m. ET
Reinhard Kandera, CFO
Igor Matushansky, CMO, Global Head R&D
https://wsw.com/webcast/jmp51/hook/1677021

[stockguard]

Analysts Set Hookipa Pharma Inc (NASDAQ:HOOK) Target Price at $11.80
https://www.tickerreport.com/banking-finance/8194946/analysts-set-hookipa-pharma-inc-nasdaqhook-target-price-at-11-80.html

[stockguard]

Biotech Is in the Dumps Because of Private Markets, One Analyst Says -- Barrons.com
10:58 am ET December 6, 2021 (Dow Jones) Print
Josh Nathan-Kazis
It's a paradox driving health-care investors to distraction: Why, in a year when biotech delivered vaccines and treatments
for the Covid-19 pandemic, more-or-less saving the world, is the sector performing so abominably on the public markets?
Over the past 12 months, while the S&P 500 index has climbed 22.7% and the S&P 500 Health Care sector index has
gained 15.9%, the iShares Biotechnology ETF (ticker: IBB), which tracks the sector with a focus on large-cap names, has
eked out a rise of just 0.4%. The SPDR S&P Biotech ETF (XBI), meanwhile, is down 19.6% over the same period.
In an email to investors late Sunday, Oppenheimer health-care equity strategist Jared Holz proposed a compelling
explanation: Blame it on the private markets.
"More and more funds are allocating dollars in the private markets and are significantly less interested with public equities
and/or stock performance as a result," Holz wrote. "Almost apathetic at times. We believe this bifurcation is the most
drastic we have ever noticed, as the private market activity has been more robust than at any time before."
What that means, Holz argues, is that early-stage private biotechs are sucking up capital. Once they go public, their
technology "has been superseded by another early-stage player looking for funding," and the private money moves on.
Investors have posited, and Barron's has written about, plenty of other explanations for the weakness in biotech: An
overheated 2020, uncertainties around the Food and Drug Administration's approval process, questions about the Federal
Trade Commission's approach to pharmaceutical mergers, the drug-pricing debate, and the slow pace of biotech M&A.
Holz writes that those may be real phenomena, but that they don't explain the sector's weakness this year, because by
and large they aren't new.
"In reality, very little has changed with respect to these issues vs. a year ago," Holz wrote. "And Biotech moved higher by
50% in FY20."
What is new, he says, is a private biotech market that is exploding. "Maybe it's not, but it feels like the amount of money
going into the private Biotech space has no ceiling," Holz writes. "This year, 500+ private Companies have received some
sort of private-stage funding; this is up more than 2x from just four years ago and is setting new record highs each day
with roughly one more month to go here in FY21."
The result has been an avalanche of biotechs going public, many of them with overinflated valuations, creating a
challenging situation for investors. Public-market investors, for their part, have lost interest in the sector, Holz writes. And
Holz argues that private investors are dropping the companies quickly as they go public.
"We would argue the quality of this year's crop is marginally weaker and perhaps not as ready for prime time, but to see
how quickly private investors jettison these stocks only to focus on the next private is perhaps the largest reconciling
item separating sector performance," he writes.
If Holz's analysis is correct, it's a study in unintended consequences for biotech. Exuberance over cutting-edge science is
drawing an avalanche of cash, but the hunt for the next Moderna (MRNA) is coming at the expense of long-term
commitment to these companies, and public investors are left holding the bag

[stockguard]

Been adding to position buying small lots during this overall biotech small cap value selloff and will re-access after next catalysts after Management over hyped IMO. Lets see if they can bring this back to life with some reasonable updates on the companies arenavirus platform without the hype behind it.

[MADDSTACKER]

What a dog , but every dog has his day ….

[MADDSTACKER]

$7.15 and we run

[MADDSTACKER]

Welcome aboard ….

[MERCURIAL]

In. Might actually be one of the few I hold for awhile.

[MADDSTACKER]

Ready for a double

[MADDSTACKER]

Merck deal isn’t moving this crazy

[stockguard]

3 “Strong Buy” Stocks Trading at Rock-Bottom Prices

Hookipa Pharma (HOOK)

Next up, Hookipa Pharma, is another clinical-stage immune-oncology research firm. Hookipa uses a proprietary platform to modify arenaviruses to carry virus-specific and tumor-specific genes directly to the patient’s T-cells, thus ‘educating’ the immune system to create the correct response. The company is using this approach to develop treatments for several serious viral diseases, including CMV, HBV, and HIV, as well as HPV-related cancer and prostate cancer.

The company has two leading research tracks. On the infectious disease front, HB-101 is a potentially prophylactic treatment against CMV – a vaccine candidate. HB-101 is currently in Phase 2 clinical trial and enrolling patients. Safety and efficacy data is expected to start coming in during 2H21.

The company also has several drug candidates in Phase 1 trials against HPV-related cancers. This is a dangerous class of cancers affecting women, and connected to the human papillomavirus. The company initiated trials for HB-201 and HB-202 late last year. Data release this past May showed acceptable safety and tolerability factors. In June, Hookipa released data on HB-200, another of its anti-cancer drug candidates. The candidate showed only 18% overall response rate – but showed antigen-specific CD8+ T cell responses described as ‘outstanding.’

Despite these ongoing trials and early data, the company’s stock plunged in June. H.C. Wainwright analyst Swayampakula Ramakanth believes the selloff was unwarranted.

“In our view, the sell-off is likely due to the lower than expected efficacy data from the cohort receiving HB-202/HB-201 alternating treatment…. However, we believe it is premature to make the call. First, all eight patients enrolled in HB-202/HB-201 cohort to date remain on the treatment, and only four of them are evaluable for efficacy, of whom, one patient achieved target tumor shrinkage of nearly 20%. Additionally, preliminary data on antigen-specific CD8+ T cells are consistent with the preclinical data. Finally, the company is still escalating the dose level for HB-202/ HB-201, and there were no dose-limiting toxicities and no Grade ≥3 treatment-related adverse events observed,” Ramakanth noted.

The analyst summed up, “Taken together, we believe HB-202/HB-201 alternating treatment still holds the potential to deliver stronger efficacy compared to HB-201 monotherapy, and the recent sell-off creates an attractive entry point for long-term investors.”

In line with these comments, the analyst rates HOOK a Buy, and his $21 price target implies a one-year upside potential of ~181%. (To watch Ramakanth’s track record, click here)

That Wall Street likes this stock is clear from the unanimous Strong Buy consensus rating. That consensus is built on 4 recent Buy reviews, which is good news for HOOK. The share are priced at $7.48 and their $23.33 average price target implies ~212%.
https://www.tipranks.com/news/article/3-strong-buy-stocks-trading-at-rock-bottom-prices-2/

[InkynClyde]

Tally Ho!

[stockguard]

04/08/2021
Hookipa Pharma initiated with an Overweight at Morgan Stanley Morgan Stanley analyst Vikram Purohit initiated coverage of Hookipa Pharma with an Overweight rating and $19 price target. Hookipa is developing candidates for cancer and infectious disease using its arenavirus platform and its initial clinical data for HB-201 in HPV16+ cancer provides early proof-of-concept, Purohit tells investors. The analyst estimates peak product sales of HB-201 in HPV16+ head and neck cancer of about $400M in 2030, assuming a launch in 2024 and assigning the program 75% odds of success. Overweight and $19 PT.

[stockguard]

Getting some love of late:
HOOKIPA PHARMA (NASDAQ HOOK) INSTITUTIONAL BUYING AND SELLING
https://www.marketbeat.com/stocks/NASDAQ/HOOK/institutional-ownership/

[stockguard]

Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside
https://seekingalpha.com/article/4396866-hookipa-data-readouts-of-2021s-hbminus-101-hbminus-201-and-hbminus-201minus-202-hold

[stockguard]

11/30/2020
Hookipa Pharma price target raised to $25 from $19 at JMP Securities
HOOK JMP Securities analyst Roy Buchanan raised the firm's price target on Hookipa Pharma to $25 from $19 and keeps an Outperform rating on the shares after the company announced interim results from the Phase 2 trial of HB-101 to vaccinate CMV- transplant patients receiving a CMV+ kidney. The analyst believes that good immune and viremia results for the three-dose group indicate that HB-101 can produce clinical benefit for this important and difficult indication, and provide additional validation of the platform.

[stockguard]

Hookipa Pharma initiated with a Buy at Truist
Truist analyst Asthika Goonewardene initiated coverage of Hookipa Pharma with a Buy rating and $21 price target. The analyst is positive on the company's efforts in building an immuno-oncology and infectious disease pipeline around its proprietary viral vector platform, which he finds "compelling" given the "profound" immune priming effect that it has demonstrated to date.

[Golden Cross]

HOOK Daily Chart

[ClayTrader]

* * $HOOK Video Chart 07-12-2019 * *

Link to Video - click here to watch the technical chart video

[Windsortrader519]

A few major pharma companies have large stakes in this company.

[Fat Thor]

Plenty of cash on hand. Great pipeline. Let's see if this can turn into a monster pharma. IPO in April.